This trial is evaluating whether EffCaMgCitrate 480 mg will improve 2 primary outcomes and 2 secondary outcomes in patients with Chronic Kidney Disease (CKD). Measurement will happen over the course of Baseline, 12 weeks.
This trial requires 36 total participants across 3 different treatment groups
This trial involves 3 different treatments. EffCaMgCitrate 480 Mg is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Chronic kidney disease is best treated using a combination of interventions. To prevent disease progression, most patients need long-term medication for controlling blood pressure, kidney function, anemia and metabolic abnormalities." - Anonymous Online Contributor
"The present study may provide the scientific evidence to claim a strong genetic connection between kidney disease and heredity, but there is a large variation of genetic predisposition between the disease groups." - Anonymous Online Contributor
"When considering clinical trials, patients should be informed to be aware of the likelihood of benefiting. When deciding whether to participate in a clinical trial, patients should consider the type of trial (monotherapeutic or multitherapeutic), the risk of harm/damage on oneself, and the type of treatment." - Anonymous Online Contributor
"This article outlines the importance of kidney disease, some of the characteristics, and some of the treatments. In the USA, approximately 1/3 of the population has a kidney disease annually. One-half of these people were diagnosed with kidney disease. Most of these end-stage kidney diseases would not go into remission. Power makes it easy to find kidney disease clinical trials tailored to your condition, treatment, or location." - Anonymous Online Contributor
"Signs of glomerulonephritis and chronic kidney disease can be present as proteinuria, hematuria and/or edema, and this can be present from the time of diagnosis." - Anonymous Online Contributor
"The most frequent treatment for kidney diseases is substitution therapy with dialysis or transplantation. New discoveries may help us to discover a new treatment option for the people affected with kidney diseases." - Anonymous Online Contributor
"The National Kidney Data System reported that there have been more than 20,000 new cases of end-stage kidney disease (ESKD) in 2009 compared with 2005. The majority of new cases occurred in patients over the age of 60, with a prevalence of 2.4/1,000 persons > age 75. Between 2005 and 2009, there was an increase, predominantly within older cohorts, in new cases of ESKD. In 2010, there was no evidence linking recent increases in tobacco use with ESKD." - Anonymous Online Contributor
"The common causes of many kidney disorders include infection, drug-related diseases, metabolic disorders, and dietary factors. A variety of other predisposing and environmental factors can be involved." - Anonymous Online Contributor
"For patients with CKD or dialysis, effcamgcitrate improves both renal disease-specific and global QOL. Effcamgcitrate may be an under-utilized therapeutic option for patients with CKD and a high risk of QOL impairments." - Anonymous Online Contributor
"The efficacies of effcamgcitrate 480 mg and a placebo for the treatment of chronic constipation in patients with chronic mild to moderate idiopathic constipation were equivalent." - Anonymous Online Contributor
"Effcamgcitrate 480 mg is safe, well tolerated, and demonstrates early pharmacodynamic biomarker efficacy in patients with stable, mild-to-moderate chronic kidney disease on chronic hemodialysis. The pharmacodynamic biomarker results are consistent with prior work with effcamgcitrate 240 mg in patients with moderate-to-severe chronic kidney disease. The clinical safety profile of effcamgcitrate 480 mg is comparable to that reported for effcamgcitrate 240 mg." - Anonymous Online Contributor
"Effcamgcitrate can cause gastrointestinal dysfunction in 4 % of patients; diarrhea in 2 %; stomatitis in 1 %; alopecia in 1 %; urticaria in 1 %; hives in 1 %; and other disturbances in 3 % of patients. In patients receiving more than 480 mg, the side effects most frequent were gastrointestinal dysfunction (5 cases), diarrhea (2), stomatitis (1), headache (1), and dysesthesia (1). Efficacy and tolerability of effcamgcitrate 480 mg were similar to those reported in previous studies. Thus, the observed adverse events were not dose-dependent." - Anonymous Online Contributor